[1] 徐淑云, 卞如濂, 陈修.主编.抗菌药物实验方法, 药理实验方法学[M].3 版.人民卫生出版社, 中国临床药理学与治疗学 2009 Dec;14(12) · 1359 · 2002:1662-1663. [2] 汪复, 张婴元.主编.实用抗感染治疗学[M].人民卫生出版社, 2004:21-22. [3] 王涛, 主编.生物医学中超微结构与电子显微镜技术[M].科学技术出版社, 1980:157-170. [4] 李家泰, 李耘, 王进.中国重症监护病房细菌耐药性监测研究[J].中华检验医学杂志, 2004, 27(11): 733-738. [5] 王玉萍, 李小宁, 王明华, 等.ICU 标本细菌培养结果及耐药性分析[J].中国临床药理学与治疗学, 2009, 13(6):691-694. [6] Xiao YH, Wang J, Li Y.Bacteria resistance surveillance in China[J].E JMicrobiol Infect Dis, 2008, 27(8):697-708. [7] Muneo H, Sayaka T, Kouju I.Comparative antibacterial activity of carbapenems against Pseudomonas aeruginosa[J].Jpn J Antibiot, 2003, 56(6):144-150. [8] Okamoto K, Gotoh N, Nishino T.Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY OprM to carbapenems:substrate specificities of the efflux systems[J].J Infect Chemother, 2002, 8(4): 371-373. [9] White R, Friedrich L, Burgess D, et al.Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa[J].Antimicrob Agent Chemother, 1996, 40(4):904-908. [10] 杨帆, 张婴元, 郑丽叶.帕尼培南-倍他米隆的临床评价[J].中华内科杂志, 2000, 39(2):107-110. [11] Muramatsu H, Horii T, Morita M.Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates[J].Int J MedMicrobiol, 2003, 293(2 3):191-197. [12] Tsuji M, Matsuda H, Miwa H.Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa:comparison of in vitro and animal models[J].J Antimicrob Chemother, 2003, 51(2):353-359 |